Bayer HealthCare Animal Health Division has Fido and Bessie's wellness in mind. The company is part of the health care division of global chemical and pharmaceutical giant Bayer. The Animal Health Division manufactures anti-infectives, insecticides, parasiticides, sedatives, nutritional supplements, vaccines, and other pharmaceuticals for companion (dogs, cats, horses) and farm (cattle, pigs, poultry, bees) animals. Major products include flea and heartworm treatment Advantage and anti-infective Baytril. The division operates more than 50 branch locations worldwide and sells its products in some 120 countries.

Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug candidate tesamorelin is a growth hormone-releasing peptide that Theratechnologies believes can combat a variety of problems, including HIV-related lipodystrophy (the metabolic syndrome characterized by changes in distribution of adipose tissue), muscle wasting associated with chronic obstructive pulmonary disease, sleep maintenance insomnia, and immune dysfunction in elderly patients.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. Oxagen’s lead compound OC000459 is a novel oral anti-inflammatory agent for the treatment of allergic disease and has successfully completed Phase IIa trials demonstrating efficacy in both asthma and allergic rhinitis. Phase IIb dose-range finding studies are currently underway. The Company is based in Milton Park, south of Oxford.

Indiana Botanic Gardens makes, markets, and sells herbal supplements, cosmetics, and other natural products.Its Botanic Choice and Botanic Spa lines feature such exotic ingredients as hoodia (an African desert plant), Indian Water Hyssop, and emu oil. In all, it sells about 1,700 items to customers throughout the US and abroad. The company does most of its business through its mail-order catalogue and online retail site; it also operates a retail store and offers wholesale sales for other retailers. Joseph E. Meyer, author of the classic reference book The Herbalist, founded Indiana Botanic Gardens in 1910. His great-grandson Tim Cleland is the company's president.

Otsuka America is US headquarters of Japan's Otsuka Pharmaceutical. Otsuka America oversees pharmaceutical research and development, marketing, and distribution of both prescription drugs and over-the-counter (OTC) medicines. The holding company's pharmaceutical subsidiaries include Otsuka America Pharmaceutical (prescription drug marketing), Otsuka Maryland Medicinal Laboratories (research), Cambridge Isotope Laboratories (chemical ingredients), and Pharmavite (nutritionals). To help wash down its pills Otsuka America also holds consumer beverage makers Crystal Geyser (bottled water), Ridge Vineyards (wine), and Soma Beverage Company (specialty bottled water).

Catalent Pharma Solutions, Inc. provides proprietary drug delivery and packaging technologies, and outsourced services to pharmaceutical, biotechnology, and consumer healthcare companies worldwide. It operates in three segments: Oral Technologies, Sterile Technologies, and Packaging Services. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products, which are used in various customer products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as tablets and capsules. The Sterile Technologies segment produces various sterile dose forms used in the prescription drug and biologic market.This segment provides formulation and development for injectables, as well as lyophilization for otherwise unstable drugs and biologics. It also fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats; and offers blow-fill-seal technology. In addition, this segment offers biologic cell line development, analytical, and scientific consulting services, as well as provides services for inhaled products. The Packaging Services segment provides various contract packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit-doses; printed components services, such as creating package inserts or folding cartons; and clinical trial supply services providing packaging, and inventory and logistics management for clinical trials. The company has a strategic alliance with Endotis Pharma to develop oral formulations of synthetic oligosaccharides. The company is based in Somerset, New Jersey.

Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s. Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and markets a variety of fertility products, including hormone treatments Bravelle, Menopur, Novarel, and Repronex. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, osteoarthritis, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, and Acthrel, a diagnostic agent for Cushing's syndrome.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Stallergenes is focused on the development, manufacture, and distribution of immunotherapeutic treatments for food-related and environmental allergies. The company has brought together experts from the fields of biology, botany, and the health community to collaborate on finding ways to deliver relief to people who suffer with problems ranging from asthma to seasonal allergies. These immunotherapy treatments involve conditioning the patient with drugs that introduce pure extracts of the allergen to initiate the body's own natural defenses against it. Wendel Investissement owns about 49% of the company. Stallergenes has research laboratories in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.